Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors

Inclusion Criteria:

* Aged 18 years or older;
* Histologically proven or cytologically confirmed SSTR positive cancers;
* Measurable disease as defined by Response Criteria in Solid Tumors (RECIST) version 1.1;
* Overexpression of somatostatin receptors of the target lesions at 68Ga-DOTA-TATE positron emission tomography (PET)/computed tomography (CT) with standard uptake value(SUV) of lesions greater than normal liver in at least 1 lesion;
* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

* Women who are pregnant or breastfeeding;
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-EB-TATE as assessed from medical records;
* Previous radioligand treatment with 177Lu-DOTA-TATE;
* Participant has had prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 4 weeks or 4 half-lives whichever is longer, before the first administration of study drug;
* Participant has not fully recovered from major surgery or significant traumatic injury prior the first dose of study drug or expects to have major surgery during the study period or within 3 months after the last dose of study drug;
* Life expectancy \< 3 months as assessed by the treating physician;
* Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements;
* The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.